In other words, the therapeutic weaponry is more limited for patients with cutaneous melanoma lacking a BRAF mutation (about 50% of all cases) and for those with rare melanoma subtypes (e.g., uveal, acral, and mucosal). This evidence concerns the gene BRAF and melanoma.